Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Oncoral Pharma

2013 FOUNDED
M&A STATUS
1-10 EMPLOYEES
M&A LATEST DEAL TYPE
Description

Developer of a novel proprietary tablet formulation designed to treat cancer. The company's formulations are composed of irinotecan, a widely used chemotherapeutic agent with a documented effect on certain solid tumors, enabling patient to overcome important side-effects of novel tablet formulation.

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Other Healthcare Services
Acquirer
Primary Office
  • Energivej 42
  • 2750 Ballerup
  • Denmark
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Oncoral Pharma’s full profile, request a free trial.

Oncoral Pharma Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 14-Sep-2017 Completed Generating Revenue
2. Grant 07-Oct-2013 Completed Startup
1. Early Stage VC 25-Sep-2013 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Oncoral Pharma Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Capnova Venture Capital Minority 000 0000 000000 0
The Danish National Advanced Technology Foundation Limited Partner Minority 000 0000 000000 0

Oncoral Pharma Board Members (1)

Name Representing Role Since Contact
Info
Hans Schambye Ph.D Self Board Member 000 0000